Dantrolene and coenzyme Q10 as a suggested combination therapy to statin-induced myopathy in high fat diet rats: A...

Area of Science:

• Biochemistry
• Pharmacology
• Toxicology

Background:

• Statin medications are widely used to lower cholesterol but can cause myotoxicity (muscle damage).
• Potential mechanisms for statin-induced myotoxicity include coenzyme Q10 (CoQ10) depletion and disrupted calcium (Ca2+) homeostasis.
• Understanding these mechanisms is crucial for developing strategies to improve statin safety.

Purpose of the Study:

• To investigate the effects of coenzyme Q10 (CoQ10) and dantrolene as adjuvant therapies to simvastatin.
• To determine if this combination can prevent or reduce simvastatin-induced myotoxicity.
• To assess the impact on biochemical markers, oxidative stress, and specific cellular pathways.

Main Methods:

• Rats were treated with simvastatin alone or in combination with CoQ10 and dantrolene.
• Serum levels of ALT, AST, and CK-MM were measured.
• Tissue Ca2+ content and oxidative stress markers were assessed.
• The TGF-β/Smad4 signaling pathway activation was analyzed.

Main Results:

• Adjuvant therapy with CoQ10 and dantrolene normalized elevated serum ALT, AST, and CK-MM levels in simvastatin-treated rats.
• The combination therapy reduced tissue Ca2+ content and suppressed simvastatin-induced oxidative stress.
• Statin's antihyperlipidemic effect remained unaffected.
• Inhibition of the simvastatin-induced TGF-β/Smad4 pathway activation was observed.

Conclusions:

• Coenzyme Q10 (CoQ10) and dantrolene show potential as adjuvant therapies to improve the side effect profile of statins.
• This combination may mitigate statin-induced myotoxicity by addressing CoQ10 depletion and calcium dysregulation.
• Further research is warranted to explore the clinical application of this adjuvant strategy.